Abstract
Much controversy surrounds the use of high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular (CV) risk. Although data regarding the association of hs-CRP with CV disease is extensive and consistent, its role in clinical practice remains unclear. The American Heart Association (AHA) recently published a scientific statement regarding criteria for evaluation of novel markers of CV risk. This article provides a comprehensive review of data regarding hs-CRP as a risk marker for CV disease in the context of these AHA criteria. The impact of the JUPITER trial on the utility of hs-CRP as a risk marker is emphasized. The review concludes with an evidence-based statement regarding the current role of hs-CRP in CV risk prediction.
MeSH terms
-
Biomarkers / analysis
-
Biomarkers / blood
-
C-Reactive Protein / metabolism*
-
Coronary Artery Disease / blood*
-
Coronary Artery Disease / diagnostic imaging
-
Coronary Artery Disease / drug therapy*
-
Coronary Artery Disease / mortality
-
Evidence-Based Medicine
-
Female
-
Fluorobenzenes / therapeutic use*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Male
-
Predictive Value of Tests
-
Pyrimidines / therapeutic use*
-
Radiography
-
Randomized Controlled Trials as Topic
-
Reproducibility of Results
-
Risk Assessment
-
Rosuvastatin Calcium
-
Severity of Illness Index
-
Sulfonamides / therapeutic use*
-
Survival Analysis
-
Treatment Outcome
Substances
-
Biomarkers
-
Fluorobenzenes
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrimidines
-
Sulfonamides
-
Rosuvastatin Calcium
-
C-Reactive Protein